Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kiora Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KPRX
Nasdaq
8731
https://kiorapharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
- Apr 11th, 2024 11:00 am
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
- Apr 5th, 2024 11:00 am
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
- Mar 28th, 2024 10:45 am
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
- Mar 25th, 2024 11:00 am
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
- Mar 8th, 2024 12:00 pm
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
- Jan 31st, 2024 11:40 pm
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties
- Jan 31st, 2024 10:15 pm
Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301
- Nov 17th, 2023 6:54 pm
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa
- Nov 9th, 2023 12:18 pm
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa
- Nov 4th, 2023 4:15 pm
Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference
- Oct 16th, 2023 11:00 am
Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa
- Oct 3rd, 2023 11:00 am
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
- Sep 21st, 2023 11:00 am
Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
- Sep 18th, 2023 11:00 am
Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
- Sep 14th, 2023 11:01 am
Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
- Sep 1st, 2023 11:00 am
Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases
- Aug 29th, 2023 5:43 pm
Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis
- Aug 23rd, 2023 11:33 pm
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
- Aug 23rd, 2023 11:00 am
Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program
- Aug 22nd, 2023 5:06 pm
Scroll